The chemokine (CK) receptor 5 (CCR5) is necessary for two adjacent cysteines (CC)-CKs such as Regulated upon Activation Normal T cell Expressed and Secreted, a/o Macrophage Inflammatory Protein 1a/b to mediate their inflammatory properties. The CCR5 gene polymorphism with 32-basepair deletion (d32) leads to receptor inactivation/ dysfunction in homo/heterozygous individuals. We have evaluated its role in both initiation and/or progression of primary immunoglobulin A (IgA) nephropathy (IGAN) in a case-control study involving a prospective cohort of 318 IGAN patients and a matched group of 294 controls. Genotyping was performed by a two-specific primers single polymerase chain reaction technique: normal allele (nl) vs d32 allele. The d32 allele frequency was not different in patients (11.0%) vs controls (8.3%), indicating no significant influence on IGAN initiation. Genotype to clinical phenotype correlation demonstrated that progression to renal/patient death was associated with the d32 allele: 18.2% (12 out of 66 with d32) vs 8.3% (21 out of 252); v 2 ¼ 6.73; P ¼ 0.017. The Kaplan-Meier survival without renal/patient death was worse in d32-positive patients (log-rank test; P ¼ 0.002). The Cox regression analyses confirmed that the nl/nl genotype was a significant and independent protective factor for progression to end-stage renal failure (ESRF)/dialysis: b/standard error (s.e.) ¼ À3.1; v 2 ¼ 9.5; relative risk ¼ 0.31 (95% confidence interval 0.15-0.65); P ¼ 0.002. The d32-CCR5 polymorphism played a significant role in the progression of primary IGAN, with the nl/nl genotype being an independent protective factor for late progression towards ESRF/dialysis. These data raise question about the usefulness of systematic CCR5 genotyping in IGAN patients.
The name chemokine (CK) results from the contraction of chemotactic cytokines. 1 CKs are classified into four different groups:
2 CXC-CKs, CC-CKs, C-CKs and CX3C-CKs, depending on their chemical structure with regard to the position of the cysteine (C) residues.
The CC-CKs family 1,2 is characterized by two adjacent cysteines and includes the following molecules: Regulated upon Activation Normal T cell Expressed and Secreted (RANTES) monocyte chemoattractant protein 1-4, and Macrophage Inflammatory Protein (MIP) 1a and 1b. Globally, these small peptides have an inflammatory, phlogistic role, with the attraction of different leucocytes, mainly monocytes, T lymphocytes, and sometimes, in addition, eosinophils/basophils, and others.
These CKs should bind CK receptors in order to mediate their biological effects through G protein interaction. To each class of CKs corresponds a class of receptors. For example, the CC-CKs have to bind to CC receptors, which are classified from 1 to 10. We focus our interest on the CC-CK receptor 5 (CCR5), 3, 4 which is specific for the CC-CKs family, but not for one molecule, because it can bind RANTES or MIP 1a or 1b. CCR5 is a seven-transmembranedomain receptor expressed constitutively on monocytes/ macrophages and on lymphocytes. So it plays a major role in leucocytes trafficking. Pathologically, the intracellular penetration of human immunodeficiency virus-1 in CD4 þ T lymphocyte is mediated by CCR5. 5 homozygous deletion (d32/d32) have been found to be resistant to human immunodeficiency virus-1 (HIV-1) infection despite regular exposure. [6] [7] [8] In fact, this mutation leads to the inactivation of the CCR5 protein, which is a necessary coreceptor for HIV intracellular penetration. 5 The CCR5 has been involved in different types of renal inflammation 9, 10 both in glomerulonephritis 11 and in renaltransplant rejection. 12 At the initiation phase, all types of intrinsic renal cells are able to secrete CKs in response to immunologic, toxic, ischemic or mechanic injuries. This will lead to persistent leucocyte infiltration and activation, especially in the interstitium, resulting in fibrosis with progression of the lesions. More precisely, in humans, CCR5-positive T lymphocytes were identified among interstitial focal infiltrates in transplant rejection, 12 in interstitial nephritis, and in different types of chronic glomerulonephritis, including immunoglobulin A (IgA) nephropathy (IGAN). 11 IGAN is the most frequent type of chronic glomerulonephritis 13 worldwide. All these data led us to study the influence of this CCR5 polymorphism on both the initiation/occurrence and the progression of the disease in our well-characterized prospective Saint-Etriune Cohort (STET-CO) of IGAN patients.
RESULTS

Genotypes and alleles distributions of CCR5 polymorphism in IGAN-STET-CO vs Controls
The genotypes distribution demonstrated a mild borderline excess of patients with d32 allele (heterozygous þ homozygous): 66 out of 318 (20.8%) vs 44 out of 294 (15.0%) in controls: w 2 ¼ 3.47; Fisher's exact test; P ¼ 0.07 (Table 1) . However, the alleles frequencies were not significantly different.
So, the d32-CCR5 polymorphism played no significant role in occurrence/initiation of the disease.
Genotypes and alleles distributions of CCR5 polymorphism according to the final clinical outcome of the patients These patients fall into three subgroups: nonprogressors (N ¼ 240), progressors (towards chronic renal failure (CRF); N ¼ 47) and major progressors (towards end-stage renal failure (ESRF)/dialysis; N ¼ 31) ( Table 2) .
The data showed a significant difference for both genotypes and alleles distributions among the three subgroups. In fact, there was a significant concentrating effect in the major progressors subgroup, with d32 allele frequency reaching 22.6 vs 9.8% in patients with no progression (Pc ¼ 0.01) and vs 8.3% in controls (Fisher exact P-value ¼ 0.001). So, there was clearly an association between d32 allele and major progression.
Progression of IGAN-STET-CO patients according to genotypes (genotype to clinical phenotype correlation)
The number of homozygous patients was very low (four of 318) (1.3%), but in accordance with the allelic frequency in the Caucasian population. These four patients were two males and two females, and two reached ESRF with dialysis (one female, one male), while two kept normal renal function.
So, for all the remaining study, we split the patients into two subgroups according to genotypes: normal allele (nl/nl) (N ¼ 252) vs with d32 allele (heterozygous þ homozygous; N ¼ 66) for the different comparisons.
At the time of diagnosis, there were no significant differences between the two subgroups 'nl/nl' vs 'with d32 allele' (Table 3) , especially for the classical independent risk factors for progression: age at onset, Global Optical Score (GOS)1, 24 h proteinuria, and hypertension (HT). However the percentage of patients with overweight/obesity was greater for the d32 allele subgroup (50.0 vs 37.7%; w 2 ¼ 3.29; P ¼ 0.09), but remained of borderline significance. Nevertheless, mean body mass index (BMI) values were not different. patients vs 12 patients with d32) exhibited no differences except for the following: the number of patients with significant crescent (C) proliferation (X10% of glomeruli with crescents) on first renal biopsy (RB1) was 8% (one out of 12; C ¼ 21%) for d32 vs 32% (six out of 19; C ¼ 11, 16, 25, 43, 57, 71%) for nl/nl (w 2 ¼ 2.7; P ¼ 0.13). In addition, no patient in the d32 subgroup vs four out of 19 (21%) in the nl/nl subgroup fulfilled the definition criteria of endo/extracapillary glomerulonephritis (X25% of glomeruli with crescents) (w 2 ¼ 2.60; P ¼ 0.10), but, overall, only 20 out of 318 (6.3%) patients had significant crescent proliferation (X10% of glomeruli with crescents) and d32 patients were older at disease onset: 44.5 (16.7) years vs 36.9 (16.7) for nl/nl patients (t ¼ À1.24; P ¼ NS).
The survival data according to Kaplan-Meier confirmed the worse survival without renal/patient death ( Figure 1 ) in patients 'with d32 allele' as compared to nl/nl patients (log rank test: w 2 ¼ 9.67; P ¼ 0.002). Divergence of the two curves was evident after 10 years from disease onset. After exclusion of all patients (N ¼ 20) with significant crescent proliferation on RB1 (e.g. exclusion of seven patients having reached the primary end point), survival without renal/patient death was significantly worse in patients with d32 allele (log rank test:
By Cox univariate analysis, we have analyzed the influence of all potential or known risk factors for progression to ESRF 
Eight patients with ESRF were excluded from this analysis (N=310); mean proteinuria is given only for proteinuric patients.
Kidney International (2006) 69, 565-572 (Table 5 ). The most powerful factors were by order: 24-h proteinuria/RB1, GOS1, absence of CRF/RB1, absence of HT/ RB1, age at disease onset and CCR5 polymorphism. The secondary end point of this study was the occurrence of CRF. Kaplan-Meier survival curves without CRF ( Figure 2 ) and according to CCR5 polymorphism also demonstrated a worse survival for patients with d32 allele (log rank test: w 2 ¼ 4.83; P ¼ 0.03). Factors influencing survival without CRF were analysed by Cox monovariate analysis (Table 6 ). 
DISCUSSION
In the normal Caucasian population, the genotype frequency is about 1% for d32/d32 (homozygous) and between 10 and 15% for the heterozygous (nl/d32). 6, 8 The results in our control group are totally in accordance: 1.7% for d32/d32 and 13.3% for d32/nl genotypes. The d32 allele frequency was found to be 4.1% in a Spanish control group (N ¼ 194), 14 13.6% in a Danish control group (N ¼ 151), 15 and 3.8% in an Italian control group (N ¼ 340) 16 vs 8.3% in our study, thus indicating large variation even in Caucasian populations.
This d32 mutation has been studied in different diseases with no significant association in asthma, 17 in multiple sclerosis, 18 in myasthenia gravis, 19 but controversial in rheumatoid arthritis. 15, 20 More recently, a Spanish study 14 was performed in systemic lupus erythematosus (N ¼ 276): overall, there was no association between CCR5 polymorphism and susceptibility to this disease; however, an SLE subgroup with biopsy-proven nephritis demonstrated a significant increase of patients bearing 'the d32 allele' (20.5 vs 8.5% in SLE without nephritis; P ¼ 0.03). This CCR5 polymorphism has also been studied in renal transplantation as a multicenter work: 21 the rare homozygous d32/d32 recipients (1.7%; N ¼ 21) had significant better graft survival vs the others (nl/nl and d32/nl). However, the heterozygous d32/nl recipients (20.2%; N ¼ 248) did not show an intermediate phenotype, as expected.
We could find only one very recent study on CCR5 polymorphism and IGAN from Panzer U et al., 22 but the results were completely opposite to ours. In that study, the d32 allelic frequency was 9.0% in the 228 preselected IGAN patients and 9.2% in the more restricted study group of 190 patients (with more demographic data), which was not so far from our finding (11.0%). The main difference was in their control group 12.4 vs 8.3% in ours, indicating the major importance of local controls. Finally, in their study, the number of IGAN patients with the d32 allele was 16.7% (38 out of 228) vs 23.5% (153 out of 651) in the controls (w 2 ¼ 4.64; Fisher exact test P ¼ 0.003), suggesting in the German population an influence of this polymorphism on initiation/occurrence of IGAN (d32 allele as protective for disease initiation/occurrence), in contrast to our findings. In addition, both survival data gave opposite results: the curves for survival without ESRF were diverging very late (after about 10 years) in our study as compared to very early (first year) in the German study; however, time zero was different: time of biopsy in their paper vs onset of the disease for us. We have no explanation for these major discrepancies; it could be the variations of the disease according to different regional populations, although these cohorts were from Western Europe and limited to Caucasian individuals. It could also be a bias of selection: only 10% of IGAN patients reaching ESRF in our cohort vs 52% in the German selection originating from 25 different centers, with 15 centers contributing less than 10 patients! In our study, the CCR5-32 bp deletion was associated with major progression toward ESRF/dialysis. The role of d32 allele appeared as complex with both early protection and late deleterious effects in d32-positive patients. Early protection could be conferred by the absence/rarity of crescent proliferation that is usually associated with a rapidly progressive course towards ESRF. In our cohort, only 20 IGAN patients (20 out of 318 ¼ 6.3%) presented with significant crescent proliferation (X10% of glomeruli) on RB1, resulting in ESRF for seven patients (seven out of 20 ¼ 35%): one d32 patient and six nl/nl patients. By contrast, the late deleterious effect was observed after longterm FU and persisting even after exclusion of 20 patients with crescent proliferation. This late effect may correspond to the final resolution/healing phase of glomerulonephritis after the more acute initial event(s). This would be a situation similar to experimental data 23 where blockade of CKs led effectively to decreased glomerular leucocyte infiltration, but overall with an aggravation/progression of the disease. In fact, multivariate analysis demonstrated that the normal variant (nl/nl) was protective and associated with better outcome and presumably less fibrosis and better healing, suggesting a direct/indirect role for CCR5 receptor on late fibrotic lesions. CCR5 polymorphism may also affect patient mortality with differences between the two variants: for example, an excess of deaths in the nl/nl patient subgroup could explain part of our results on disease progression. In fact, CC-CK and CC-CK receptors are playing a role in atherosclerosis. More precisely, CCR5 and macrophage inflammatory protein 1b are present in human arterial smooth muscle cells and in macrophages of atherosclerotic plaques. 24 In addition, individuals bearing the d32 deletion seemed to be protected for early myocardial infarction or severe coronary artery disease. 25 In our cohort, we have observed only two deaths before reaching ESRF.
There might be other possible explanations for our finding. The d32 variant might be in linkage disequilibrium with the putative gene(s) involved in IGAN progression. So, the deleterious effect observed in our study could have been an indirect one. On the contrary, if the d32 allele was a real gene for progression in IGAN, we could imagine the following sequences: IGAN is often initiated after different acute/subacute infections; such infections would trigger the CKs system and, more precisely, the CC-CKs; these CKs will have decreased activity because of the CCR5 receptor dysfunction (no function at all for rare homozygous and decreased function for heterozygous carriers); this will prevent from making an acute, but self-limited nephritis with, finally, a good recovery after few months. The rare crescentic lesions observed in IGAN might represent the exacerbated form of such acute nephritis in IGAN; our observation that crescentic proliferation needs to have an intact CCR5 receptor might be an indirect argument for this presumed mechanism. Patients with d32 allele could have a persistent low-level infection, with inappropriate immune response of the IGA type (IGAN background), chronic stimulation, and finally chronic fibrotic renal lesions. In our IGAN-STET-CO, we could not demonstrate any significant differences in serum IGA level, between the nl/nl and the d32 groups or related to CRF or ESRF progression.
With the same prospective cohort IGAN-STET-CO, we have performed other gene polymorphisms, including tumour necrosis factor a 26 and G protein b3 subunit 27 , and none showed a significant influence on progression.
We are well aware of conflicting results concerning association between initiation and/or progression of IGAN on one hand, and, on the other hand, different gene polymorphisms concerning human lymphocyte antigens or molecules of the renin-angiotensin system (mainly insertion/ deletion for angiotensin-converting enzyme) or uteroglobin or others. There are well-known ethnic variations in incidence and/or prognosis of IGAN. Nevertheless, these discrepancies often concerned the same ethnic group (for example, Caucasian) and have been addressed for angiotensinconverting enzyme (I, D) with finally negative data, 28 but also as a systematic review. 29 The case-control study should include large homogeneous cohorts, but the transmission disequilibrium test should be preferred whenever possible. There is currently a debate on genetic association with complex diseases. [30] [31] [32] In this study, we have tried to avoid the classical pitfalls: the number of patients and controls is obviously not small, but of medium size; our IGAN-STET-CO included all types of prognosis without any selection; the mean FU time was more than 10 years; the percentage of patients lost to FU was below 10% and the percentage of patients available for DNA analysis was 83% (318 out of 385).
Obviously, our results need to be confirmed on a larger prospective cohort of IGAN incident cases with longer FU. Our findings also raise the question about systematic CCR5 genotyping of patients with biopsy-proven IGAN. The cost is limited, but will the future patients with d32 allele benefit from closer FU and may be more aggressive treatment?
CONCLUSION
In this study, we could not demonstrate any significant role of the d32-CCR5 polymorphism in initiation/occurrence of primary IGAN. By contrast, the d32 allele was significantly associated with late progression of this disease toward ESRF with dialysis. In fact, multivariate analysis demonstrated that the nl/nl genotype was a significant and independent protective factor for ESRF/dialysis.
MATERIALS AND METHODS
This is a case-control study to detect significant association(s) and compare one group of IGAN patients to a control group. Each individual gave informed consent to this genetic study.
Prospective cohort of IGAN patients
This group included 318 consecutive patients (220 males, 69.2%) with the diagnosis of biopsy-proven IGAN carried out in our department during the years 1988-1999 (incident cases) with at least 1 þ IgA mesangial deposits on routine immunofluorescence. We have restricted our analysis to primary IGAN, also called Berger's disease, and so excluded all patients with IGAN secondary to Schönlein-Henoch purpura, liver cirrhosis, or lupus erythematosus. In addition, we have excluded five patients with Berger's disease because of nonhomogenous ethnic origin (patients from NorthAfrica or non-Caucasian). All these 318 patients belong to a prospective cohort of patients recruited from the Saint-Etienne area (IGAN-STET-CO) and regularly were followed up in our department. This is not a natural history cohort, but this cohort includes the whole spectrum of patients with Berger's disease (mild, severe, rapidly progressive courses). These patients were adequately treated/ managed for arterial HT and/or proteinuria 41 g/day and/or severe pathological lesions if any; in fact, 55.1% (118) of patients were receiving angiotensin-converting enzyme inhibitors and/or angiotensin II receptor antagonist at last FU for HT a/o proteinuria, and 86 (27%) had received high-dose steroid treatment for a few months for severe pathological lesions.
Onset of the disease was recorded as the occurrence/discovery of the first renal sign such as gross hematuria a/o microscopic hematuria, a/o proteinuria a/o nephrotic syndrome and a/o CRF. The mean (standard deviation (s.d.)) and median age at onset were, respectively, 34.8 (15.0) and 33.4 years.
The RB1 (diagnosis) was performed at a mean time of 63.7 (94.0) and a median time of 26.8 months after onset of the disease. At the time of diagnosis, the mean (s.d.) and median age of the patients were, respectively, 40.6 (14.1) and 39.7 years for females, and 39.9 (15.1) and 40.2 years for males. In all, 93 patients (29.2%) had proteinuria greater than 1 g/day, with only 27 (8.5%) with proteinuria over 3 g/24 h. Also, 102 patients (32.1%) were already hypertensive (defined as blood pressure over 140/90 mmHg at two different occasions and/or thereafter treated); 63 (19.8%) had some degree of CRF defined as calculated creatinine clearance according to Cockcroft-Gault formula below 60 ml/month for more than 3 months. 33 Distribution of the estimated GFR indicated 42 patients in stage 3, 13 patients in stage 4, and already eight patients in stage 5.
The mean (s.d.) and median total exposure times (from onset of the disease to either last visit or renal/patient death) were 147.9 (106.0) months and 127.4 months (e.g. more than 10 years). At the last FU, 144 (45.3%) were hypertensives, 78 (24.5%) had some degree of CRF, with 31 (9.7%) in ESRF and needing dialysis (end point). In addition, two patients died before reaching ESRF -one male who died 81.4 months after disease onset from car accident, at age 23.3 years, with a stage 1 GFR, and one female who died 557.7 months after disease onset from asthma/infection, at age 70.8 years, with already a stage 4 GFR (17 ml/month). So finally, the total number of primary events was 33 (10.4%), with 31 renal deaths and two patient deaths.
The controls
The control group was matched for gender to fit the male predominance in the IGAN-STET-CO.
A total of 294 healthy, local, Caucasian, unrelated volunteers were enrolled: 206 males (70.1%) and 88 females.
Clinical and pathological data of the IGAN-STET-CO patients
Clinical data. We have collected at the time of RB1 and at last FU the following parameters: 24 h proteinuria, plasma creatinine (mmol/l) (with calculation of creatinine clearance (ml/min) according to Cockcroft-Gault formula), height (m), weight (kg) with calculation of body mass index (weight/height 2 ¼ kg/m 2 ). In addition, the presence of HT and CRF was recorded.
Pathological data. The RB1 was scored according to previous experience. 34, 35 We used the GOS ranging from 0 to 20, which was the sum of glomerular (0-6), vascular (0-5), interstitial (0-5), and tubular (0-4) indices.
Clinical progression. The primary combined end point of this study was renal death (occurrence of ESRF with the need for dialysis; all these patients were GFR stage 5 with a calculated creatinine clearance below 10 ml/min at the time of first dialysis session) or patient death occurring before ESRF/dialysis. The secondary end points were CRF and HT.
For the purpose of comparing genotypes and alleles distribution of CCR5 polymorphism according to the final clinical outcome, we have stratified all these patients in three different subgroups. The stratification was based upon staging of calculated GFR at last FU: the subgroup with GFR stages 1 and 2 (normal) was considered as nonprogressor, subgroup with GFR stages 3 and 4 as progressor (towards CRF), and subgroup with GFR stage 5 as major progressor (towards ESRF).
Genotyping of CCR5 d32 polymorphism Genomic DNA was isolated by standard procedures from 5 ml of venous peripheral blood drawn on EDTA.
Genotyping was performed by single polymerase chain reaction using two specific primers. Each tube contained 250 ng of DNA (1 ml) and 20 pmol of CCR5-specific primer sense: 5 0 -TCAAAAAG AAGGTCTTCATTACACC-3 0 and of primer antisense: 5 0 -AGCCCA GAAGAGAAAATAAACAATC-3 0 in a 50-ml reaction volume. Reaction conditions per cycle were the following: denaturation at 941C for 15 s, annealing at 581C for 20 s, elongation at 721C for 30 s, and 30 cycles were run. Reaction products were separated on 3% agarose gel (Nusieve) stained with ethidium bromide and visualized under ultraviolet light. The normal wild allele (nl) corresponded to one band of 241 bp and the deleted mutant (d32) allele to one band of 209 bp. So we could identify three genotypes: nl/nl with one single 241 bp band, nl/d32 with two bands: 241 and 209 bp, and d32/d32 with one single 209 bp band. All genotypes from patients and controls with d32 allele were controlled in a separate assay and all confirmed without exception.
Statistical analysis
Genotypes/alleles comparisons between patients and controls and comparisons between subgroups of IGAN patients (nonprogressor; progressor; major progressor). All analyses were carried out with Statview 5.0 (Abacus Concepts Inc., Berkeley, CA, USA). The distributions of the genotypes (nl/nl; nl/d32; d32/d32) and alleles (nl, d32) were compared using contingency tables and standard w 2 tests. The power of such comparison between patients and controls was over 90%, based on the total number of alleles (individuals Â 2) with a risk a ¼ 0.05, a risk b ¼ 0.10 and permitted a detection of a 10% difference in allelic frequencies.
Clinicopathological parameters according to different genotypes. The quantitative (continuous) variables such as proteinuria (g/day), body mass index and plasma creatinine were compared with either t-test for unpaired groups or nonparametric tests such as Mann-Whitney U-test, when applicable.
The qualitative (category) variables such as class of proteinuria, class of body mass index, class of GFR and events like HT, CRF and ESRF (dialysis) were compared using w 2 contingency table.
Survival curves without an event. Survival curves without renal/patient death were built with the Kaplan-Meier method and according to the different CCR5 genotypes (nl/nl vs with d32 allele) and compared by the log rank test: renal or patient death was the event; time zero was the onset of the disease; the final date was either the event occurrence date or the date of last FU for censored patients.
All factors influencing survival data, including CCR5 genotypes, were tested by Cox univariate analysis. In case of significant difference(s), forward stepwise proportional hazard Cox regression model 36 (multivariate analysis) was used with all significant covariates and at least the already known independent risk factors for progression, 35 such as age at onset, 13 arterial HT, GOS, 24-h proteinuria and body mass index. 37 
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